Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease-Reference-Cited by-同舟云学术

Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease

Published:2023-12 Issue: Volume:218 Page:115900
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Biagioli Michele^ORCID,Marchianò Silvia,Di Giorgio Cristina,Bordoni Martina,Urbani Ginevra,Bellini Rachele,Massa Carmen,Sami Ullah Khan Rana,Roselli Rosalinda,Chiara Monti Maria,Morretta Elva,Giordano Antonino,Vellecco Valentina,Bucci Mariarosaria,Jilani Iqbal Asif,Saviano Anella,Ab Mansour Adel,Ricci Patrizia,Distrutti Eleonora,Zampella Angela,Cieri Enrico,Cirino Giuseppe,Fiorucci Stefano^ORCID

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference77 articles.

1. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?;Younossi;Hepatology,2022

2. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention;Younossi;Nat. Rev. Gastroenterol. Hepatol.,2018

3. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis;Targher;J. Hepatol.,2016

4. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis;Wu;Sci. Rep.,2016

5. Nonalcoholic fatty liver disease and cardiovascular disease;Przybyszewski;Clin. Liver Dis.,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseases;Pharmacological Research;2024-10

2. Bile acid metabolism in health and ageing-related diseases;Biochemical Pharmacology;2024-07

3. Screening and identification of key biomarkers associated with endometriosis using bioinformatics and next generation sequencing data analysis;2024-05-08

4. Update on the development of TGR5 agonists for human diseases;European Journal of Medicinal Chemistry;2024-05

5. A microbial derived bile acid acts as GPBAR1 agonist and RORγt inverse agonist and reverses inflammation in inflammatory bowel disease;2024-04-11